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INTRODUCTION:  Paraganglioma  is  a malignant  tumor  that  arises  from  the  extra  adrenal  paraganglionic
cells  of  the  sympathetic  or parasympathetic  systems.  Herein,  we  present  a  case  of abdominal  mass  of
unknown  histology  that  underwent  a  very  difﬁcult  surgical  mass  resection.  Its ﬁnal  histologic  diagnosis
was non-functional  paraganglioma  that  was  presented  as  a huge  intra-peritoneal  mass.
PRESENTATION  OF  CASE:  The  patient  was  a 55-year-old  Iranian  lady  who  referred  to our  center  with
a  giant  abdominal  mass.  Fine  needle  aspiration  (FNA)  biopsy  showed  undifferentiated  carcinoma.  After
laparotomy  for  mass  resection  pathology  evaluation  revealed;  malignant  paraganglioma,  non-metastatic
type.  Further  post-operative  patients  evaluations  showed  that the  tumor  was  sporadic  in nature  and  the
subsequent  patient’s  natural  history  was  uneventful.
DISCUSSION: Pathologic  evaluations  have  key  roles  in the  exact  diagnosis  of abdominal  masses  with
unidentiﬁed  sources.  For  the paragangliomas,  all  of them  should  be  regarded  malignant  until  proved
otherwise.  However,  combined  use of  biochemical  markers,  immunohistochemical  techniques  (IHC),  and
genetic  analysis  have  key  roles  in  the diagnosis  and  treatment  of paragangliomas.  Additionally,  surgical
removal  is  the  proved  curative  way  of paraganglioma  treatment.
CONCLUSION:  Asymptomatic  intra-peritoneal  paraganglioma  is  very  rare,  especially  its  malignant  vari-
ety.  This case  emphasizes  that  full  pathologic  investigation  would  reveal  the exact  nature  of  idiopathic
abdominal  masses,  especially  in  the  state  of  absence  of  typical  clinical  and  para-clinical  symptoms.
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. Case presentation
The patient was a 55-year-old Iranian woman  who  admitted
ue to a vague abdominal pain, anorexia, and weight loss. The
atient’s symptoms were begun since one year before admission.
n past medical history only a long history of rheumatic valvular
eart disease was noted. No familial history of any disease was
eported. In physical examination, patient’s body mass index (BMI)
as 20. In cardiac examination, atrial ﬁbrillation was  detected
ue to rheumatic valvular problems. In echocardiography aortic
egurgitation concomitant with its stenosis and mitral regurgita-
ion was found. The cardiac ejections fraction was 25%. In drug
istory chronic oral digoxin use concomitant with warfarin tablets
as noted. Hemoglobin level was 10 g/dl and other lab data was
nremarkable. Blood pressure was normal and no history of vas-
ular hypertension was reported. In abdominal examination some
pper quadrant abdominal mass without identiﬁable borders was
oted. In abdominopelvic ultrasonography a large upper abdom-
nal soft tissue mass was detected. Abdominopelvic CT scan with
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oral and intravenous contrast was  performed and a 15–12 cm het-
erogeneous contrast enhanced mass was  detected that its location
was in front of left kidney and spleen (Fig. 1). An ultrasound guided
ﬁne needle biopsy was performed. The pathologic diagnosis was in
favor of undifferentiated carcinoma.
The patient scheduled for the operation with full cardiologic
and hematologic preparation. The cardiac consultation revealed
that the risk of surgery is high, and her ASA score was three, so
the consent form received from the patient and her relations. The
laparatomy performed with an upper midline incision. The mass
was anterior to the left kidney inside peritoneum. Its adhesions
were released from adjacent organs such as descending colon, gas-
tric wall and the body of pancreas, meticulously. Due to severe
adhesions of the mass to the spleen concomitant splenectomy
was performed, too. The weight of mass without spleen was  550 g
(Fig. 2). The pathologic study was done with the routine Hema-
toxylin and Eosin (H&E) staining and immunohistochemistry (IHC)
study (Fig. 3). A neoplastic tissue was seen that was composed
of Zellballen nests of cells with scant amphophilic cytoplasm and
enlarged nuclei with focal pleomorphism and atypia. Some mitotic
ﬁgures, extensive areas of necrosis and capsular invasion are iden-
Open access under CC BY-NC-ND license.tiﬁed. The IHC study showed synaptophsin and chromogranin
A positivity in tumoral cells, patchy positivity of EMA, and pan
cytokratin, positivity of ki 67 in 20% of tumoral cells, and ﬁnally
negativity of melan A, vimentin, and CD 10. The predominant cell
BY-NC-ND license.
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Fig. 1. Preoperative abdominopelvic CT scan reve
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10Fig. 2. Surgical specimen, the mass with its adhesive spleen is evident.
ype was small cell type, with capsular invasion and without any
ascular invasion. The spleen was free of tumor.
Finally, paraganglioma with malignant behavior was identiﬁed.
o genetic study was performed for the patient. After a one month
ollow-up, 24 h urinary biochemistry study was performed. The uri-
ary epinephrine, norepinephrine, vanillil mandelic acid (VMA),
nd dopamine were measured. All of them were in the upper lim-
ts of normal. For eradication of suspicious residual tumors, 132I
IBG radionuclide therapy was performed. The patient was  well
nd without any recurrence on 3 months (Fig. 4) and one year after
peration.
. Discussion
Pheochromocytomas are tumors that arising from chromaf-
n cells of the adrenal medulla. They are called paraganglioma if
hromafﬁn-cell tumors originate from extra-adrenal sites along
he sympathetic and/or the parasympathetic chain.1 Paragan-
lioma may  be located at any place from the cervical region to
he pelvic cavity.2 They secrete and store catecholamines caus-
ng some symptoms (functional tumors); some of them, especially
arasympathetic paragangliomas, may  be non-functional.3,4 They
ay present at all ages with a peak incidence around 30–50
ears. Clinical incidences of pheochromocytomas have been esti-
ated to range between 0.4 and 9.5 per million per year and
2,5,6.5 per million per year in the case of paragangliomas. Extra-
drenal paraganglioma (EAP) rate of malignancy is more than
ntra-adrenal paragangliomas, especially if related to succinate
ehydrogenase B mutations (SDHB).7,8 One study showed that 55%aling a huge heterogenous abdominal mass.
of paraganglioma are malignant, and 83.3% of them had genetic
mutation.9 This is in contrast to the intra-adrenal paraganglioma
that its malignancy rate is 10%.7 They are potentially malignant
catecholamine-secreting tumor involving the adrenal glands in
90% of cases and an extra-adrenal origin in 10%. Diagnosis of
pheochromocytoma/paraganglioma is usually performed by clini-
cal presentation and elevated catecholamine levels of serum and/or
urine or their metabolites.10 High plasma levels of chromogranin
A have been suggested to be indicative of malignancy.11 Although
pheochromocytomas are catecholamine secreting tumors, but 17%
of cases are asymptomatic as of our case.12 In the state of secre-
tory tumors the most common symptoms are headache, sweating,
tachycardia or palpitations, dyspnea, nausea and chest pain.10 The
asymptomatic cases pose a diagnostic dilemma. Imaging is usu-
ally the best for anatomic localization especially in the case of
non-secretory tumors. Plasma catecholamine levels more than
2000 pg/ml are indicative of pheochromocytoma. Measurement of
urinary epinephrine levels has the highest sensitivity (85%).13 How-
ever, metanephrines measurement may  fail to diagnose tumors
that secrete minute amounts of catecholamines and tumors that
secrete just dopamine.14 Surgical excision of all tumors with
involved tissues is the primary treatment of choice because these
tumors are commonly chemo- and radioresistant.10 The only abso-
lute indication of malignancy may  be distant metastasis to the
organs such as liver, bone and lymph nodes. Certain histological
features such as invasion; vascular and/or capsular, conﬂuent or
focal necrosis, diffuse growth or large nests, high cellularity nuclear
pleomorphism and hyperchromasia are suggestive of malignancy.2
Several possible characteristics are suggested as predictors of
malignancy: tumor weight more than 80 g and high concentration
of dopamine inside the tumor, tumor size more than 5 cm (75%
predictive).3 Ki-67 proliferative index more than 6% is most com-
mon  in malignant tumors.15 In addition, the expression of cell cycle
related genes such as P53 and Ki-67 might be of help.16 The Ki-67
positivity of our case was  more than 20%. All paragangliomas should
be regarded potentially malignant because of difﬁculty in conﬁrm-
ing malignancy. Patients with malignant paragangliomas can only
be cured by surgery.2 The transabdominal approach is advised
in large and malignant suspicious tumors.3The recurrence rate
of paragangliomas are more than pheochromocytoma, therefore
long term follow up is needed. Sometimes, preoperative diagno-
sis of renal or adrenal masses imposes some diagnostic dilemma,
therefore complete preoperative evaluation is recommended.17,18
Frequent blood pressure measurement in adjunct with urinary cat-
echolamine measurement is mandatory for the surveillance.
In the case of malignant paragangliomas postoperative radionu-
clide treatment should be initiated to eradicate the residual tumors
or micro metastases. Radionuclide treatment can be done by
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Fig. 3. Histology (A) H&E stained slide showing Zellballen nests of cells with focal pleom
20%  of cells (×20). (C) Positive cytoplasmic and membranous immunoreactions for synap
(E)  Negative immunoreaction for vimentin (×20). F) Negative immunoreaction for CD 10
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pFig. 4. Follow up CT scan 3 months after operation.
eta-emitting isotopes coupled to either MIBG or somatostatin
2nalogs. The ability of radiolabeled MIBG to enter the cell mem-
ranes and storing in cytoplasmic granules via VMA  transporters
VMAT1, 2) made them suitable for its using as a treatment of
aragangliomas.19 Sixty percent of metastatic sites uptakes it20 andorphism and atypia (×20). (B) Positive nuclear immunoreaction for Ki 67 in about
tophysin (×20). (D) Positive cytoplasmic immunoreaction for chromogranin (×20).
 (×20).
it can be used as an adjuvant therapy for eradication of residual
disease shortly after debulking surgery.21 131I-MIBG radionuclide
therapy in single or fractionated doses can be applied. Near 60%
of metastatic foci demonstrated 30% partial objective response to
I-MIBG therapy20 and the remaining 40% were stable.
In spite of multi-modality treatments the overall 5-year survival
remains low with a reported value of 50%.22 The use of biochemical
markers, immunohistochemical techniques, and genetic analysis
all have key roles in the early diagnosis, assessment and treatment
of paragangliomas/pheochromocytomas.2 Disick and Palese23 in
their study concluded that paraganglioma rate of recurrence and
metastases are higher than their adrenal counterparts, making their
continuous follow-up more essential.
3. Conclusion
Malignant paraganglioma are rare cancers that its diagnosis and
treatment impose some difﬁculty to the treating physicians. In
these situations, implementation of team working can facilitate the
proper diagnosis and treatment. Based on the best of our knowl-
edge, this is the ﬁrst reported case of the intra-peritoneal malignant
paraganglioma. Our patient managed properly with the surgical
debulking and radionuclide adjuvant therapy in spite of general
opinion about their curative effect.Conﬂicts of interest
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